Further survival analysis showed that high levels of tumor-infiltrating lymphocytes (TILs) were associated with markedly longer survival outcomes in OS (CD4 naïve T cells: 24.07 vs. 8.00 months, p < 0.001; CD8 T cells: 24.07 vs. 8.37 months, p=0.004; Figure 6B) and intrahepatic PFS (CD4 naïve T cells: 18.10 vs. 6.83 months, p=0.002; CD8 T cells: 18.10 vs. 8.00 months, p < 0.001; Figure 6C). Here, CD8A is linked to neoplasm.